Although early stage precancerous lesions already appear to harbor driver genes mutations like KRAS and TP53, suggesting that these gene alterations play an important role in tumor onset and progression, genomic analysis of resection specimens represents only a snapshot of existing mutations [30,31]. The gene discussed is KRAS; the disease is neoplasm.